<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen W Seely, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Camille E Powe, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erika F Werner, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H9014674"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The terms "pregestational diabetes" and "preexisting diabetes" refer primarily to type 1 or type 2 diabetes mellitus diagnosed prior to pregnancy. Pregestational diabetes complicates approximately 1 to 2 percent of all pregnancies and accounts for 13 to 21 percent of diabetes in pregnancy, with the remainder due to gestational diabetes [<a href="#rid1">1,2</a>]. The proportion of pregnant patients with type 1 and type 2 diabetes reflects the prevalence of these disorders in the specific population. While rates of both type 1 and type 2 diabetes appear to be increasing [<a href="#rid3">3,4</a>], type 2 diabetes is more prevalent than type 1 diabetes in most populations, the prevalence is rapidly increasing, and accounts for a larger proportion of pregestational cases [<a href="#rid5">5,6</a>].</p><p>Type 1 and type 2 diabetes carry a significantly elevated risk of adverse maternal and fetal outcomes, including congenital malformations, early pregnancy loss, preterm birth, preeclampsia, macrosomia, and perinatal mortality [<a href="#rid7">7-9</a>]. Hyperglycemia is the primary driver of these risks, and studies repeatedly show that tight glycemic control in the periconceptional period and during pregnancy is associated with improved outcomes [<a href="#rid7">7,10,11</a>]. </p><p>Prior to pregnancy, all females of childbearing age with type 1 or type 2 diabetes should be counseled about the potential effects of diabetes and their medications on maternal and fetal outcomes and the potential impact of pregnancy on their diabetes control and any existing complications. Preconception care can improve glycemic control in early pregnancy and, in turn, reduce the risk for some adverse pregnancy outcomes, such as congenital anomalies [<a href="#rid12">12</a>].</p><p>This topic will describe the potential maternal and fetal complications associated with pregnancy in females with preexisting diabetes and will discuss preconception risk counseling, evaluation, and management of these patients. Care during pregnancy is reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4441.html" rel="external">"Pregestational (preexisting) and gestational diabetes: Intrapartum and postpartum glucose management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4806.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Obstetric issues and management"</a>.)</p><p></p><p class="headingAnchor" id="H812232655"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>The key components of preconception diabetes management are:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient education</p><p class="bulletIndent1"><span class="glyph">●</span>Glycemic control</p><p class="bulletIndent1"><span class="glyph">●</span>Proficient diabetes self-care</p><p class="bulletIndent1"><span class="glyph">●</span>Medical optimization of preexisting complications and comorbidities associated with diabetes</p><p></p><p>Comprehensive and ongoing patient education is critical for shared decision-making about management goals and medication changes and for helping patients meet the considerable demands of self-care.</p><p>The intense medical and lifestyle regimens that must be undertaken before and during pregnancy and worry over pregnancy outcome can have an impact on the individual's psychological well-being. While preexisting depression does not appear to worsen during pregnancy for patients with pregestational diabetes, emotional distress (fear, worry, self-blame) can interfere with their enjoyment of pregnancy [<a href="#rid13">13,14</a>]. In the case of prior fetal loss or congenital malformation, patients may also experience grief, guilt, and postpregnancy depression. For this reason, it is important that preconception counseling, evaluation, and management be conducted with a patient-centered approach that emphasizes patient support and minimizes treatment-related distress.</p><p class="headingAnchor" id="H812232689"><span class="h1">RISK COUNSELING</span><span class="headingEndMark"> — </span>Risk counseling involves discussion of potential fetal, neonatal, obstetric, and maternal adverse outcomes.</p><p class="headingAnchor" id="H2309360897"><span class="h2">Risks with type 1 versus type 2 diabetes</span><span class="headingEndMark"> — </span>Pregnancy outcomes are generally similar for patients with type 1 versus type 2 diabetes. Although patients with type 2 diabetes generally have milder glycemic disturbance, lower pregestational glycated hemoglobin (A1C), and a shorter duration of disease than those with type 1 diabetes, this does not necessarily result in better fetal/neonatal outcomes because they are also likely to have a higher preconception body mass index and older age at conception, which are risk factors for adverse pregnancy outcomes independent of diabetes status [<a href="#rid15">15</a>]. (See <a class="local">'Fetal and neonatal risks'</a> below and <a class="local">'Obstetric complications'</a> below.)</p><p>While the risk of pregnancy complications may be similar, there are some important differences in risk of maternal complications. Patients with type 1 diabetes are more likely to have pregestational microvascular complications that can worsen due to pregnancy, and they are at higher risk of developing severe hypoglycemia and diabetic ketoacidosis. Microvascular complications also increase the risk for some pregnancy complications, such as fetal growth restriction (FGR)/small for gestational age (SGA) infant. (See <a class="local">'Growth restriction'</a> below.)</p><p class="headingAnchor" id="H9014694"><span class="h2">Fetal and neonatal risks</span><span class="headingEndMark"> — </span>Fetal and neonatal complications among patients with pregestational diabetes range in severity from potentially mild (large for gestational age [LGA] infant) to lethal (higher risk of early pregnancy loss, some congenital malformations, and stillbirth). The risk of these complications is directly related to glycemic control throughout pregnancy.</p><p>Although the impact of preconception glycemic control on adverse pregnancy outcomes in patients with pregestational diabetes has not been examined in randomized trials for ethical reasons, existing observational data strongly suggest that glucose control from the periconceptional period to birth can reduce these risks. In fact, the risks for congenital malformations and some causes of perinatal mortality can be reduced to levels close to those of patients without diabetes [<a href="#rid7">7,16,17</a>].</p><p class="headingAnchor" id="H9014700"><span class="h3">Congenital malformations</span><span class="headingEndMark"> — </span>In patients with pregestational diabetes, the overall risk of congenital malformations is consistently reported to be two- to fourfold higher than that in those without diabetes  (<a class="graphic graphic_table graphicRef108112" href="/d/graphic/108112.html" rel="external">table 1</a>) and is strongly related to the degree of hyperglycemia in the periconceptional period. Overall rates of major congenital malformations in pregnant individuals with type 1 diabetes range from 2.9 to 7.5 percent compared with 2.1 to 12.3 percent in those with type 2 diabetes; periconceptional hyperglycemia is associated with the high end of the range [<a href="#rid7">7,18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 1997 pregnancies resulting in live births from seven cohort studies, the risk of congenital abnormalities increased with increasing hemoglobin A1C, and the absolute risk of a pregnancy affected by a congenital anomaly was [<a href="#rid19">19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A1C 5.5 percent: 2 to 3 percent</p><p class="bulletIndent2"><span class="glyph">•</span>A1C 7.6 percent: 4 percent</p><p class="bulletIndent2"><span class="glyph">•</span>A1C ≥14 percent: 20 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study of a cohort of pregnant people with type 1 or type 2 diabetes in the United Kingdom, for every 1 percent absolute decrease in maternal A1C, there was a 30 percent reduction in risk of major congenital malformations [<a href="#rid20">20</a>].</p><p></p><p>Pregestational diabetes is associated with a substantially increased risk for major congenital anomalies in all organ systems [<a href="#rid21">21</a>]. The spectrum of major congenital anomalies observed in pregnant people with pregestational diabetes is similar to that in those without diabetes, with some exceptions. The most common abnormality is congenital heart disease (including tetralogy of Fallot, transposition of the great arteries, septal defects, and anomalous pulmonary venous return), which accounts for 35 to 40 percent of major congenital anomalies in pregnancies with pregestational diabetes [<a href="#rid19">19,22</a>]. Central nervous system anomalies (eg, anencephaly, spina bifida, encephalocele, hydrocephaly, anotia/microtia) are the second most common category of anomaly, followed by anomalies in the urogenital system.</p><p>On the other hand, sacral agenesis/caudal dysplasia (lack of fetal development of the caudal spine and corresponding segments of the spinal cord) is rare in the general population but highly associated with maternal diabetes (adjusted odds ratio [OR] 80, 95% CI 46-139 [<a href="#rid21">21</a>]), which accounts for 15 to 25 percent of all cases of sacral agenesis [<a href="#rid23">23</a>].</p><p>The pathogenesis is unclear. Maternal diabetes may change genes involved in signaling and metabolic pathways essential for normal embryonic development [<a href="#rid24">24-26</a>]. These pathways may involve folate metabolism, oxidative stress, apoptosis, and proliferation. For example, in hyperglycemic animal models, embryopathy appears to be related to induction of high levels of oxidative stress, which leads to dysregulation of gene expression and excess apoptosis in developing organs [<a href="#rid27">27</a>]. The cardiovascular, central nervous, and skeletal systems are particular targets of this process. In addition, pregestational diabetes and obesity often occur together and obesity is an independent, more modest risk factor for development of congenital anomalies [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management", section on 'Congenital anomalies'</a>.)</p><p class="headingAnchor" id="H1767423842"><span class="h3">Preterm birth</span><span class="headingEndMark"> — </span>Infants delivered preterm are at increased risk of respiratory distress syndrome and a variety of other complications related to preterm birth, especially in the setting of poor maternal glycemic management. (See  <a class="medical medical_review" href="/d/html/4965.html" rel="external">"Overview of short-term complications in preterm infants"</a> and  <a class="medical medical_review" href="/d/html/5033.html" rel="external">"Overview of the long-term complications of preterm birth"</a> and  <a class="medical medical_review" href="/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>.)</p><p>Pregnancies complicated by pregestational diabetes mellitus are at significantly higher risk of both medically and obstetrically indicated preterm birth and spontaneous preterm birth compared with those without diabetes [<a href="#rid9">9,29,30</a>].</p><p>In a Swedish population-based cohort study including over 2400 pregnant people with type 1 diabetes [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The overall incidence of preterm birth in those with and without diabetes (&gt;2400) was 22.3 and 4.7 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence was higher at every level of A1C, progressively increasing from 13 percent at A1C &lt;6.5 percent to 37.5 percent at A1C ≥9.1 percent, for A1C measured any time from 90 days before to 91 days after conception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The increase in preterm birth among pregnant people with diabetes was primarily related to indicated preterm birth (adjusted relative risk [RR] 9.1), but spontaneous preterm birth was also increased (adjusted RR 2.6) compared with pregnant people without diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary outcomes, including LGA infant, macrosomia, neonatal hypoglycemia or respiratory distress, low Apgar score, and stillbirth or neonatal death, were also increased, but the relationship was not linear.</p><p></p><p>Although these findings affirm and expand upon previous data on the association between type 1 diabetes and adverse pregnancy outcomes, questions remain regarding the role of periconceptional glucose control versus other factors (eg, maternal obesity, second- and third-trimester glucose control, nonglucose-mediated effects) in this association and whether a target A1C &lt;6.5 percent is adequate.</p><p class="headingAnchor" id="H9014724"><span class="h3">Large for gestational age/macrosomia</span><span class="headingEndMark"> — </span>Accelerated fetal growth is common in pregnancies complicated by pregestational diabetes. The infant may be LGA (ie, &gt;90<sup>th</sup> percentile for gestational age) or, less commonly, macrosomic (variously defined as fetal/newborn weight above 4000 grams, 4500 grams, or 10 pounds). In a prospective study of 340 pregnant patients with type 1 diabetes, the frequencies of LGA and macrosomia (defined as &gt;4000 grams) were 41 and 18 percent, respectively [<a href="#rid31">31</a>].</p><p>The body composition of LGA/macrosomic infants of mothers with pregestational diabetes differs from those born to those without diabetes. They are more likely to have a higher percentage of body fat, larger shoulders and extremity circumferences, and a lower head-to-shoulder ratio and head circumference (HC)-to-abdominal circumference (AC) ratio (HC/AC &lt;1) than infants of similar weight and length of mothers without diabetes. The reasons for these differences in body composition are unclear but are thought to be caused by increased maternal transfer of substrates (eg, glucose, amino acids), leading to fetal hyperinsulinemia and subsequent effects of insulin on target tissues to promote growth and store excess nutrients as adipose tissue [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/4443.html" rel="external">"Fetal macrosomia"</a>.)</p><p>Macrosomia is of concern because macrosomic fetuses are at increased risk of shoulder dystocia and birth trauma (eg, brachial plexus injury, fracture) if delivered vaginally. Many are delivered by cesarean either electively or because of abnormal labor progress (see  <a class="medical medical_review" href="/d/html/4472.html" rel="external">"Shoulder dystocia: Risk factors and planning birth of high-risk pregnancies"</a> and  <a class="medical medical_review" href="/d/html/5397.html" rel="external">"Shoulder dystocia: Intrapartum diagnosis, management, and outcome"</a>). Both LGA and macrosomia also have long-term consequences. (See  <a class="medical medical_review" href="/d/html/5059.html" rel="external">"Large for gestational age (LGA) newborn"</a>.)</p><p>The pathogenetic factors leading to LGA/macrosomia appear to be triggered in early pregnancy but are also present across gestation [<a href="#rid33">33</a>]. Glucose control periconceptionally and in the first trimester, in addition to later pregnancy glycemic control, appears to have an impact on the risk of LGA/macrosomia [<a href="#rid34">34</a>]. Glycemic variability, gestational weight gain, prepregnancy obesity, and maternal lipid levels also play a role in birth weight. (See  <a class="medical medical_review" href="/d/html/4443.html" rel="external">"Fetal macrosomia", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H812233426"><span class="h3">Growth restriction</span><span class="headingEndMark"> — </span>Although less common than LGA/macrosomia, pregestational diabetes is also associated with an increased risk for failure of the fetus to achieve its genetic growth potential, which is termed FGR or SGA and variously defined as weight &lt;3<sup>rd</sup>, 5<sup>th</sup>, or 10<sup>th</sup> percentile. The risk is higher in pregnant patients with type 1 versus type 2 diabetes and related to prevalence of diabetic vasculopathy, particularly when severe. In the prospective study of 340 pregnant patients with type 1 diabetes discussed above, the frequency of FGR/SGA in patients with no vasculopathy, hypertension, and/or background retinopathy was 4 out of 261 (1.5 percent) versus 8 out of 80 (10 percent) among those with proliferative retinopathy and/or nephropathy [<a href="#rid31">31</a>].</p><p>FGR/SGA is important because it is associated with increased fetal/neonatal mortality and short- and long-term morbidity. (See  <a class="medical medical_review" href="/d/html/6768.html" rel="external">"Fetal growth restriction: Evaluation"</a> and  <a class="medical medical_review" href="/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a>.)</p><p class="headingAnchor" id="H812233495"><span class="h3">Other neonatal morbidity</span><span class="headingEndMark"> — </span>Neonatal medical complications associated with maternal pregestational diabetes include hypoglycemia, erythrocytosis, hyperbilirubinemia, hypocalcemia, respiratory distress, and cardiomyopathy. These complications are discussed separately. (See  <a class="medical medical_review" href="/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>.)</p><p class="headingAnchor" id="H812232946"><span class="h3">Perinatal mortality</span><span class="headingEndMark"> — </span>Perinatal mortality is increased in pregnancies complicated by pregestational diabetes, and the risk begins to increase at A1C levels between 6 and 6.9 percent [<a href="#rid10">10,11</a>]. Although the risk for perinatal death appears to be similar for pregnancies with type 1 and type 2 diabetes, the underlying causes of death appear to differ:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of nonanomalous singleton offspring of pregnant people with preexisting diabetes in the North of England from 1996 to 2008 (type 1 diabetes: 1206; type 2 diabetes: 342), fetal or infant death (ie, death from 20 weeks of gestation to one year of life) occurred in 3.6 percent of these pregnancies versus 1 percent of pregnancies without preexisting diabetes and was not significantly different for type 1 versus type 2 diabetes [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of perinatal loss in 341 pregnant people with type 1 and 862 pregnant people with type 2 diabetes, perinatal deaths associated with type 1 diabetes were primarily related to congenital abnormalities or complications of preterm birth, whereas those associated with type 2 diabetes were more likely to be due to stillbirth, birth asphyxia, or intraamniotic infection [<a href="#rid16">16</a>].</p><p></p><p>Among pregnant people with type 2 diabetes, rates of perinatal mortality do not appear to vary with duration of disease [<a href="#rid35">35</a>]; pregnant people with type 2 diabetes first recognized in pregnancy appear to have rates similar to those with longstanding diabetes [<a href="#rid16">16,36</a>].</p><p>Improvements in perinatal mortality over time in some studies (eg, stillbirth decreased from approximately 26 to 29 out of 1000 births in 2002 and 2003 to 11 out of 1000 births in 2015 in the United Kingdom [<a href="#rid37">37</a>]) have probably been related to improvements in the provision and uptake of prepregnancy care and tighter glycemic targets [<a href="#rid38">38</a>]. If glucose and risk factor control are optimal, perinatal death rates may approach those of pregnant people without diabetes [<a href="#rid39">39</a>]; however, a small excess risk of perinatal death has been observed even among pregnant people with good glycemic control [<a href="#rid10">10,11,16</a>].</p><p class="headingAnchor" id="H9014736"><span class="h3">Long-term outcomes</span><span class="headingEndMark"> — </span>Maternal diabetes has potential long-term impacts on offspring health. Offspring of mothers with diabetes are at increased risk of developing diabetes, obesity, and other adverse cardiometabolic outcomes [<a href="#rid40">40-43</a>]. The diabetes type (1 or 2) in offspring is related, in part, to maternal and paternal diabetes status. Increasingly, however, studies suggest an increased risk of obesity and type 2 diabetes in offspring of pregnant people with pregestational diabetes independent of genetic factors and possibly due to the effects of the uterine environment on neonatal programming [<a href="#rid40">40,44-46</a>]. It is unclear whether cognitive and other neurodevelopmental outcomes of offspring are affected by maternal diabetes. Pregestational and gestational diabetes have been linked with an increased risk of autism in offspring [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)", section on 'Long-term outcome'</a> and  <a class="medical medical_review" href="/d/html/595.html" rel="external">"Autism spectrum disorder (ASD) in children and adolescents: Terminology, epidemiology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H9014742"><span class="h2">Obstetric complications</span></p><p class="headingAnchor" id="H812233165"><span class="h3">Early pregnancy loss</span><span class="headingEndMark"> — </span>Rates of early pregnancy loss are two- to threefold higher in pregnant people with pregestational diabetes than among those without diabetes. Possible reasons for this higher risk include an increased rate of congenital malformations, toxic effects of hyperglycemia, and maternal vascular disease leading to uteroplacental insufficiency [<a href="#rid10">10,18,49</a>].</p><p>Aneuploidy, a common cause of early pregnancy loss, does not appear to be a factor because the risk of having an aneuploid fetus seems to be the same in pregnant people with and without diabetes. However, it is possible that epigenetic changes in gene expression may be influenced by pregestational diabetes; this is an area of ongoing investigation [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/5439.html" rel="external">"Pregnancy loss (miscarriage): Terminology, risk factors, and etiology"</a>.)</p><p class="headingAnchor" id="H1058001477"><span class="h3">Preeclampsia and gestational hypertension</span><span class="headingEndMark"> — </span>The risks of both preeclampsia and gestational hypertension are three- to fourfold higher in pregnant people with pregestational diabetes than those without (for preeclampsia: 12 to 20 percent versus 5 to 7 percent) [<a href="#rid50">50-52</a>]. Pregnant people with type 1 diabetes are at the high end of this range or even higher (50 percent) since preexisting microvascular disease is more prevalent in these patients, and it is a major risk factor for pregnancy-induced hypertensive disorders [<a href="#rid18">18,53</a>].</p><p>Although preconception glucose status does not appear to affect risk of preeclampsia and gestational hypertension, evidence suggests that good glycemic control during pregnancy decreases this risk [<a href="#rid51">51,54</a>]. Use of low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, beginning at the end of the first trimester, also reduces risk. In patients with prepregnancy diabetes, the American Diabetes Association (ADA) recommends initiating prophylaxis at 12 to 16 weeks of gestation at a dose of 100 to 150 mg/day (taking two 81 mg tablets [162 mg] is also acceptable if 100 to 150 mg dosing is not available) [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention"</a> and  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p class="headingAnchor" id="H1058001608"><span class="h3">Polyhydramnios</span><span class="headingEndMark"> — </span>Polyhydramnios (excessive amniotic fluid) occurs more frequently in pregnancies associated with pregestational diabetes, especially those with suboptimal glycemic control or an LGA fetus [<a href="#rid56">56</a>]. In one study of 314 singleton pregnancies &gt;24 weeks in patients with pregestational diabetes, 19 percent had polyhydramnios [<a href="#rid56">56</a>]. It occurs in 1 to 2 percent of the general obstetric population and has been associated with a variety of adverse obstetric outcomes. (See  <a class="medical medical_review" href="/d/html/6781.html" rel="external">"Polyhydramnios: Etiology, diagnosis, and management in singleton gestations"</a>.)</p><p>The mechanism for polyhydramnios in pregnancies complicated by diabetes is unclear. Fetal hyperglycemia leading to polyuria is one likely etiology and is supported by the observation that polyhydramnios is often associated with high maternal A1C levels and fetal macrosomia [<a href="#rid56">56,57</a>]. Decreased fetal swallowing or an imbalance of water movement between the maternal and fetal compartments are other possible mechanisms.</p><p class="headingAnchor" id="H1058005688"><span class="h3">Cesarean birth</span><span class="headingEndMark"> — </span>Although maternal diabetes is not an indication for cesarean birth in the absence of the usual obstetric indications, pregnant patients with pregestational diabetes (type 1 or 2) are at higher risk of undergoing cesarean birth than those in the general obstetric population, in part because of their higher rates of LGA, preeclampsia, and obesity [<a href="#rid16">16</a>].</p><p>Pregnant people with type 2 diabetes appear to be at lower risk for cesarean birth than those with type 1 diabetes (in one meta-analysis: OR 0.80, 95% CI 0.59-0.94 [<a href="#rid35">35</a>]) but are still at increased risk compared with those with euglycemia. (See  <a class="medical medical_review" href="/d/html/4806.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Obstetric issues and management", section on 'Route'</a>.)</p><p class="headingAnchor" id="H1058001756"><span class="h2">Maternal medical risks</span></p><p class="headingAnchor" id="H1161045126"><span class="h3">Hypoglycemia</span><span class="headingEndMark"> — </span>Pregnant people with pregestational diabetes treated with insulin are at increased risk for severe hypoglycemia in early pregnancy compared with prepregnancy and later in pregnancy [<a href="#rid58">58,59</a>]. This is thought to be due to the lower glucose targets in pregnancy accompanied by an increase in insulin sensitivity [<a href="#rid60">60,61</a>] and often erratic meals due to nausea and/or vomiting of pregnancy [<a href="#rid62">62</a>]. (See <a class="local">'Glycemic control'</a> below.)</p><p class="headingAnchor" id="H9014748"><span class="h3">Progression of microvascular disease</span><span class="headingEndMark"> — </span>The likelihood of worsening microvascular complications in pregnancy is related to duration of diabetes and prepregnancy glycemic control [<a href="#rid63">63</a>]. Although two large prospective studies of females with type 1 diabetes, the Diabetes Control and Complications Trial (DCCT) [<a href="#rid64">64</a>] and the EURODIAB Prospective Complications Study [<a href="#rid65">65</a>], suggest that pregnancy alone is not a risk factor for the de novo development of microvascular complications, pregnancy can exacerbate preexisting microvascular disease, and this effect varies by type of complication.</p><p class="headingAnchor" id="H9014754"><span class="h4">Diabetic retinopathy</span><span class="headingEndMark"> — </span>The majority of pregnant people with diabetic retinopathy will not experience clinically important worsening of retinopathy during or following pregnancy. However, for some, particularly those with proliferative retinopathy (marked by new retinal vessel growth), retinopathy may worsen during pregnancy ("transient worsening") because of often rapid intensification of glycemic control and pregnancy-related vascular, volume, and hormonal changes. For a small subset of patients with severe pregestational retinopathy, visual changes may persist postdelivery.</p><p>The likelihood of retinopathy progression is related to maternal duration of diabetes, presence and severity of pregestational retinopathy, and to the degree of glycemic control prior to and during pregnancy. Hypertension, smoking, hyperlipidemia, and hypoglycemia have also been associated with acceleration of retinopathy in pregnancy [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/1783.html" rel="external">"Diabetic retinopathy: Classification and clinical features", section on 'Prevalence and natural history'</a>.)</p><p>As in nonpregnant patients, rapid tightening of glycemic control has been associated with worsening retinopathy in pregnant patients with pregestational diabetes [<a href="#rid63">63,67</a>]. Worsening of retinopathy in this setting is thought to be mediated by closure of small retinal blood vessels, which were narrowed but patent prior to tightening of glucose control. Correction of hyperglycemia may lower intravascular volume, leading to vessel closure. In most pregnant people, the benefits of normoglycemia for the fetus far outweigh the modest and generally transient deterioration in retinopathy from improved glycemic control since milder forms of diabetic retinopathy typically improve after birth. However, some patients with severe proliferative retinopathy or with macular edema may experience persistence or even further progression of retinopathy postpregnancy [<a href="#rid67">67</a>].</p><p>These relationships were illustrated by the Diabetes in Early Pregnancy (DIEP) study, a prospective study of 140 pregnant people with pregestational diabetes (all with type 1 diabetes) and no proliferative retinopathy at periconceptional baseline examination [<a href="#rid68">68</a>]. At follow-up examination one month postpartum, progression of retinopathy was noted in 20 percent of patients with microaneurysms or mild nonproliferative retinopathy at baseline and 55 percent of those with moderate to severe nonproliferative retinopathy [<a href="#rid68">68</a>]. Proliferative retinopathy developed in 6 percent of patients with mild baseline retinopathy and 29 percent of patients with moderate to severe baseline retinopathy. Ten percent of patients without retinopathy at baseline had signs of retinopathy postpartum on funduscopic examination.</p><p>Data on impact of antepartum progression of retinopathy on the clinically meaningful outcome of postpartum vision are scant. One study reported postpartum patients with diabetes had worse visual acuity as measured by letter recognition at nine weeks after birth compared with nonpregnant females with diabetes followed for the same interval; however, the vision decrement was small, suggesting the impact of pregnancy in most pregnant patients with pregestational diabetes is minimal [<a href="#rid69">69</a>]. The vision change was reported for all subjects with diabetes and pregnancy, without correlation to progression or severity of retinopathy; thus, impact of pregnancy on vision in higher-risk subgroups remains unclear.</p><p class="headingAnchor" id="H9014760"><span class="h4">Diabetic kidney disease</span><span class="headingEndMark"> — </span>Patients with diabetes and normal albumin excretion are at low risk for development of kidney disease in pregnancy. Patients with diabetes, moderately increased albuminuria (formerly microalbuminuria), and normal kidney function appear to be at low risk for loss of kidney function during pregnancy but may have a transient increase in albuminuria. For example, in the DCCT study, females with diabetes in the intensive treatment arm who became pregnant had an increase in albumin excretion rate, whereas those in the conventional arm did not [<a href="#rid64">64</a>]. Among patients with overt proteinuria at baseline, urinary protein excretion can rise dramatically as pregnancy progresses, but after birth, protein excretion decreases in most individuals.</p><p>By contrast, patients with poorly controlled hypertension or reduced glomerular filtration rate and heavy proteinuria (serum creatinine level &gt;1.5 mg/dL, proteinuria &gt;3 grams in 24 hours) at the onset of pregnancy are at risk of permanent kidney damage, including end-stage kidney disease. As many as 40 percent of patients with serum creatinine &gt;3 mg/dL or creatinine clearance &lt;50 mL/minute will develop permanent worsening of renal function with pregnancy [<a href="#rid70">70</a>].</p><p>Diabetic kidney disease also carries risks for the pregnancy. Both moderately increased albuminuria (formerly microalbuminuria) and overt nephropathy are associated with an increased rate of preterm birth, primarily due to preeclampsia. Hypertension and preeclampsia are associated with growth restriction and (rarely) fetal or maternal death. In a meta-analysis of 12 studies of patients with type 1 or 2 diabetes, the frequency of preeclampsia in those with versus without kidney disease was 48.6 and 13.1 percent, respectively [<a href="#rid71">71</a>].</p><p>Issues relating to pregnancy in patients with diabetic kidney disease are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H9014772"><span class="h3">Cardiovascular disease</span><span class="headingEndMark"> — </span>Pregnant people with pregestational diabetes are at increased risk of macrovascular cardiac disease (eg, coronary artery disease, heart failure, stroke) and microvascular cardiac disease (eg, microvascular angiopathy, cardiac autonomic neuropathy). The risk is related both to diabetes and to the frequent presence of other cardiovascular and renal risk factors, such as hypertension and nephropathy [<a href="#rid72">72-74</a>]. In addition, pregnancy-related volume expansion may unmask previously subclinical disease, such as asymptomatic diastolic dysfunction. (See  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Screening for coronary heart disease'</a>.)</p><p class="headingAnchor" id="H1058002242"><span class="h3">Peripheral and autonomic neuropathy</span><span class="headingEndMark"> — </span>Pregnancy does not appear to affect the course of peripheral or autonomic neuropathy. However, autonomic neuropathy can complicate pregnancy since affected individuals are at increased risk of hyperemesis gravidarum (related to gastroparesis), hypoglycemia unawareness, and orthostatic hypotension. (See  <a class="medical medical_review" href="/d/html/5272.html" rel="external">"Screening for diabetic polyneuropathy"</a> and  <a class="medical medical_review" href="/d/html/5280.html" rel="external">"Management of diabetic neuropathy"</a> and  <a class="medical medical_review" href="/d/html/5285.html" rel="external">"Diabetic autonomic neuropathy"</a>.)</p><p>Recognizing the presence of gastroparesis before pregnancy is important because it can lead to extreme hypo- and hyperglycemia, increased risk of diabetic ketoacidosis, weight loss, and malnutrition in the absence of appropriate management. In addition, the clinical manifestations of gastroparesis may be confused with hyperemesis of pregnancy. The effects of gastroparesis can be mitigated by utilizing dietary modification, adjusting the insulin regimen, and other medical therapies (eg, antiemetic and prokinetic agents). Patients with significant gastroparesis who become pregnant often have frequent hospitalizations and may require <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/2643.html" rel="external">"Diabetic autonomic neuropathy of the gastrointestinal tract"</a> and  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p class="headingAnchor" id="H9014778"><span class="h3">Diabetic ketoacidosis</span><span class="headingEndMark"> — </span>Diabetic ketoacidosis is more common, occurs at lower levels of glycemia, and carries a higher risk of mortality in pregnant versus nonpregnant females with type 1 diabetes. It can occur at glucose values ≤250 mg/dL (13.9 mmol/L) because the increased insulin resistance and lipolytic state of pregnancy, coupled with compensated respiratory alkalosis with decreased ability to buffer ketoacids, render pregnant people more prone to ketoacidosis [<a href="#rid72">72,75,76</a>].</p><p>Diabetic ketoacidosis has been reported in 1 to 10 percent of pregnant people with type 1 diabetes and may be fatal. The risk of fetal demise is substantial: Rates of 9 to 35 percent have been reported [<a href="#rid77">77,78</a>]. Other complications include sequelae of fetal hypoxia and acidosis, preterm birth, and maternal and/or neonatal intensive care unit admission [<a href="#rid79">79</a>].</p><p>Diabetic ketoacidosis can occur in ketosis-prone type 2 diabetes but is rare in pregnancy [<a href="#rid80">80</a>]. In addition to the usual precipitants of diabetic ketoacidosis, potential pregnancy-related causes include treatment with beta-mimetic tocolytics and antenatal corticosteroids. (See  <a class="medical medical_review" href="/d/html/138420.html" rel="external">"Diabetic ketoacidosis in pregnancy"</a>.)</p><p class="headingAnchor" id="H1058002514"><span class="h1">PRECONCEPTION EVALUATION AND MANAGEMENT</span></p><p class="headingAnchor" id="H3614076310"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Preconception planning is the foundation for a successful outcome of pregnancy in females with pregestational diabetes. In a meta-analysis of 12 cohort studies that evaluated the effectiveness and safety of preconception care in improving maternal and fetal outcomes for individuals with preexisting diabetes, preconception care was associated with a lower first-trimester glycated hemoglobin (A1C) level (average reduction 2.43 percent, 95% CI 2.27-2.58) and significantly reduced rates of congenital malformations (14 out of 896 [1.6 percent] versus 110 out of 1512 [7.3 percent], relative risk [RR] 0.25, 95% CI 0.15-0.42), preterm birth (61 out of 209 [29 percent] versus 155 out of 374 [41 percent], RR 0.70, 95% CI 0.55-0.90), and perinatal mortality (5 out of 381 [1.3 percent] versus 28 out of 634 [4.4 percent], RR 0.35, 95% CI 0.15-0.82) [<a href="#rid81">81</a>]. However, individuals who participate in preconception planning are likely to be different from those who did not, and therefore, the improvement ascribed to prepregnancy care may be reflective of differences in populations [<a href="#rid82">82</a>]. No randomized trials of preconception care versus no care have been performed.</p><p>Preconception counseling should be tailored to the patient's type of diabetes (type 1 or type 2) and take into account the patient's personal history of diabetic complications. Preconception care should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Counseling about the impact of glycemic status on maternal-fetal outcome, the risk of development or progression of preexisting complications of diabetes, and the types and risks of adverse maternal, fetal, and neonatal outcomes. (See <a class="local">'Risk counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Helping patients achieve good glucose control, with A1C in the normal range if safely achievable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Explaining that preconception glucose control is important because congenital malformations induced by hyperglycemia (diabetic embryopathy) occur in the first few weeks of pregnancy before patients know they are pregnant [<a href="#rid11">11,83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjusting medications (eg, antihypertensive drugs, oral antihyperglycemic agents) as needed for fetal safety.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beginning <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation (at least 400 micrograms per day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluating for comorbidities and complications of diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiating treatment of comorbidities and complications or optimizing the status of existing medical conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discussing and providing effective contraception to avoid unplanned pregnancy until glucose control is achieved.</p><p></p><p>In females with advanced complications of diabetes, weighing the risk of a pregnancy to their health versus the desire for childbearing is particularly important. For example, those at risk for deteriorating renal function leading to dialysis may decide not to pursue becoming pregnant.</p><p>The following text describes issues of preconception evaluation and management specific to females with diabetes. Routine aspects of preconception care applicable to all females are reviewed separately. (See  <a class="medical medical_review" href="/d/html/448.html" rel="external">"The preconception office visit"</a>.)</p><p class="headingAnchor" id="H9014802"><span class="h2">Glycemic control</span></p><p class="headingAnchor" id="H2472627763"><span class="h3">Target glucose levels</span><span class="headingEndMark"> — </span>Successful preconception care programs have used the following preconception glucose targets [<a href="#rid70">70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Before meal capillary blood glucose concentration: 80 to 110 mg/dL (4.4 to 6.1 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Two-hour postprandial glucose concentration: &lt;155 mg/dL (8.6 mmol/L)</p><p></p><p>Although still quite low, these targets are slightly higher than pregnancy targets and probably more pragmatic for patients who are not yet pregnant. Glucose self-monitoring is an important tool for achieving the tight glucose control needed in pregnancy. (See  <a class="medical medical_review" href="/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus"</a> and  <a class="medical medical_patient" href="/d/html/1744.html" rel="external">"Patient education: Glucose monitoring in diabetes (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H1717315538"><span class="h3">Target A1C level</span><span class="headingEndMark"> — </span>Our preconception A1C goal for all patients with diabetes is &lt;6.5 percent. The American Diabetes Association (ADA) recommends aiming for an A1C &lt;6.5 percent (48 mmol/mol), and the Endocrine Society recommends aiming for an A1C level "as close to normal as possible" (ie, &lt;6.5 percent [48 mmol/mol]) without causing undue hypoglycemia [<a href="#rid55">55,84</a>]. There are limited high-quality clinical trial data on the effects and risks/benefits of very low A1C levels during pregnancy.</p><p>Patients with diabetes should be encouraged to allow a minimum of three to six months to achieve optimal glucose control before trying to conceive, if glucose levels are not already well controlled.</p><p class="headingAnchor" id="H1061833877"><span class="h3">Insulin therapy</span><span class="headingEndMark"> — </span>In patients with type 1 or type 2 diabetes, insulin remains the standard drug for glucose management during pregnancy. In patients with type 2 diabetes taking noninsulin antihyperglycemic agents, insulin is often started preconception to attain the optimal degree of glycemic control while allowing discontinuation of noninsulin agents without safety data in early pregnancy [<a href="#rid85">85</a>].</p><p>In the preconception period, we suggest using insulins with a good fetal safety profile, such as neutral protamine hagedorn (NPH), lispro, aspart, and detemir insulins. <a class="drug drug_general" data-topicid="9023" href="/d/drug information/9023.html" rel="external">Insulin glargine</a>, a long-acting insulin, has greater mitogenic potential and higher affinity in binding to the insulin-like growth factor 1 receptor than other insulins [<a href="#rid86">86</a>], which could lead to increased fetal growth and macrosomia. However, small observational studies in humans do not support this concern [<a href="#rid87">87-89</a>]. <a class="drug drug_general" data-topicid="104418" href="/d/drug information/104418.html" rel="external">Insulin degludec</a> has not been well studied in pregnancy, though a case series including 22 pregnancies did not suggest an increased risk of adverse perinatal outcomes in pregnant people using this basal insulin as compared with insulin glargine [<a href="#rid90">90</a>]. We also suggest avoiding premixed insulins, which are more difficult to titrate to achieve desired levels of glycemic control without hypoglycemia.</p><p>Given the availability of better-studied and effective alternatives, we consider substituting NPH insulin or <a class="drug drug_general" data-topicid="9022" href="/d/drug information/9022.html" rel="external">insulin detemir</a> for <a class="drug drug_general" data-topicid="9023" href="/d/drug information/9023.html" rel="external">insulin glargine</a> or degludec prior to pregnancy. If this is not desirable due to patient preference, insurance coverage, or inability to achieve optimal glucose control on an alternative regimen, we discuss the theoretic risks of insulin glargine or degludec on pregnancy and help the patient make an informed decision. The amount of observational data supporting the safety of glargine are greater than that for <a class="drug drug_general" data-topicid="104418" href="/d/drug information/104418.html" rel="external">insulin degludec</a>. A randomized trial comparing glycemic control and outcomes with the use of insulin degludec versus insulin detemir in pregnancy is near completion [<a href="#rid91">91</a>]. </p><p>For a short-acting insulin, we generally use a rapid-acting insulin, such as lispro or aspart, instead of <a class="drug drug_general" data-topicid="9030" href="/d/drug information/9030.html" rel="external">regular insulin</a>. These insulins have a rapid onset, which improves control of the postprandial increase in glucose, and have a rapid offset, which may decrease hypoglycemia. A randomized trial of rapid-acting aspart versus regular insulin in pregnancy demonstrated less of a glucose rise postprandially with aspart than regular insulin, but there was no significant difference in hypoglycemia rates [<a href="#rid92">92</a>]. Glulisine has not been well studied in pregnancy, thus we generally avoid it. Faster-acting <a class="drug drug_general" data-topicid="9020" href="/d/drug information/9020.html" rel="external">insulin aspart</a> and ultra-rapid lispro also do not have data supporting their use in pregnancy or preconception. Of note, a systematic review of different types and regimens of insulin in pregnancy did not find superiority of any type/regimen over another [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Insulin pharmacotherapy'</a>.)</p><p>If a nonpregnant female is considering switching to insulin pump therapy, initiation should ideally occur prior to attempts at conception to allow ample time for training, acclimatization to pump use, and troubleshooting before pregnancy. We generally avoid switching patients to pump therapy during pregnancy because of the risks for significant hypo- or hyperglycemia (including diabetic ketoacidosis) during the transition period.</p><p>One group that ran two parallel trials of continuous glucose monitoring (CGM), one in pregnant patients with type 1 diabetes and the other in patients with type 1 diabetes planning pregnancy, reported that pregnancy outcomes were not significantly improved for patients who began CGM during pregnancy planning, possibly due to the small sample size [<a href="#rid94">94</a>]. However, CGM during pregnancy resulted in improved pregnancy outcomes. Nevertheless, CGM may be helpful to some patients trying to achieve glucose control preconception, and this decision should be made on a case-by-case basis. While some CGM devices can be used to dose insulin without additional self-monitoring of glucose, this has not been studied in the preconception period or during pregnancy; thus, many clinicians consider CGM only as an adjunct to traditional self-monitoring.</p><p class="headingAnchor" id="H4204728841"><span class="h4">Patients on preconception insulin pumps</span><span class="headingEndMark"> — </span>Patients already using insulin pumps can continue to use them as they attempt to conceive and during pregnancy. Of note, at least one study suggested multiple daily injections of insulin were superior to pump therapy in achieving lower A1C levels [<a href="#rid95">95</a>]. There may be individual exceptions (eg, patients with poor glucose control on multiple dose injections), with some patients obtaining better glucose control with pump therapy initiated during pregnancy. </p><p>We generally continue sensor-augmented pump therapy (with automatic suspension of insulin delivery for hypoglycemia), though this has not specifically been evaluated in pregnancy. In contrast, hybrid closed-loop devices, which provide automatic adjustments to basal insulin delivery rates with or without automatic correction boluses for high-sensor glucose levels, have not been studied in pregnancy. Moreover, they do not allow users to adjust the target glucose lower to accommodate pregnancy glycemic goals [<a href="#rid96">96</a>]. Patients using hybrid closed-loop devices who desire pregnancy should be counseled that use is off-label in pregnancy and that they may need to turn off these features or obtain a new pump to achieve pregnancy glycemic goals. In select cases, for example, where control would be poor without the aid of the hybrid closed-loop algorithm, we use shared decision-making with patients to determine whether to continue the hybrid closed-loop device in the preconception period and during pregnancy.</p><p class="headingAnchor" id="H3438465743"><span class="h3">Patients on preconception noninsulin antihyperglycemic agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metformin</strong>,<strong> </strong><strong>glyburide</strong> – Insulin remains the preferred therapy of diabetes in pregnant patients. However, for patients with type 2 diabetes on <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> monotherapy with glycemic control at goal for preconception, we suggest continuing metformin through the first trimester and adding insulin to achieve pregnancy glycemic goals once pregnancy is confirmed. Studies of metformin use in the first trimester suggest that it is not teratogenic [<a href="#rid97">97-100</a>] and use of metformin may help maintain glycemic control during the period of organogenesis. Insulin is likely to be required in addition to or instead of metformin to achieve the level of glycemic control recommended in pregnancy. Consideration can be given to continuing metformin beyond the first trimester [<a href="#rid101">101</a>], but there are concerns related to transplacental passage and metabolic effects in children exposed in utero; this issue is covered separately. (See  <a class="medical medical_review" href="/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Patients on noninsulin antihyperglycemic agents prior to pregnancy'</a>.)</p><p></p><p class="bulletIndent1">For patients on other noninsulin antihyperglycemic agents, we suggest switching to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and/or insulin therapy prior to conception. While <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">glyburide</a> has been studied in gestational diabetes and was previously the most frequently prescribed agent for this indication, its use is declining because of evidence of transplacental transfer [<a href="#rid102">102</a>] and a possible increase in the risk of adverse outcomes in comparison with insulin [<a href="#rid103">103</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GLP-1 agonists, SGLT-2 inhibitors, and DPP-4 inhibitors</strong> – There are limited data for other commonly used non-insulin agents such as GLP-1 agonists, SGLT-2 inhibitors, and DPP-4 inhibitors, which should be avoided. An increased frequency of congenital malformation or other harmful effects on the human fetus has not been observed [<a href="#rid104">104</a>], but animal studies have reported increased occurrence of fetal damage. For example, in animals, SGLT-2 inhibitors have caused renal toxicity at developmental periods equivalent to the second and third trimesters in humans and GLP-1 agonists have caused vascular (heart, blood vessels) and skeletal (cranial bones, vertebra, ribs) abnormalities at maternal exposures below the maximum recommended human dose. </p><p></p><p class="headingAnchor" id="H584039697"><span class="h3">Management of hypoglycemia</span><span class="headingEndMark"> — </span>It is important to review signs and symptoms of hypoglycemia (eg, tremor, palpitations, anxiety/arousal, sweating, hunger, dizziness, weakness, drowsiness, confusion) with the patient, as well as actions the patient (and close contacts) should take if hypoglycemia develops.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be instructed to carry a snack at all times.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If patients have a history of hypoglycemia or begin to experience hypoglycemia when tightening glucose control, they should be given a prescription for <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> and taught or retaught how to administer it.</p><p></p><p>Reinforcement of hypoglycemia management is particularly important prepregnancy so that the patient is prepared in early pregnancy, when the frequency of hypoglycemia may increase due to tightened glucose control, changes in hormone levels, nausea and vomiting of pregnancy, and reduction in physical activity. Hypoglycemia is more likely to occur in patients with type 1 diabetes due to autoimmune destruction of the alpha cells that produce <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>.</p><p>The symptoms, risk factors, prevention, and treatment of hypoglycemia in adults with diabetes are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/1805.html" rel="external">"Hypoglycemia in adults with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H9014828"><span class="h2">Diet, weight, and exercise</span><span class="headingEndMark"> — </span>Diet is one of the most important behavioral aspects of diabetes treatment. Referral to a registered dietitian is usually helpful for patients with diabetes who are planning pregnancy. Understanding how different food intakes affect glycemia and developing a food plan of meals and snacks help reduce glucose fluctuations and manage fluctuations that occur. Nutritional considerations for patients with type 1 and type 2 diabetes are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1765.html" rel="external">"Nutritional considerations in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1766.html" rel="external">"Nutritional considerations in type 2 diabetes mellitus"</a>.)</p><p>Patients who are overweight or have obesity should be encouraged to lose weight prior to conception. In addition to improving prepregnancy glycemic control and potential benefits on metabolic profile (eg, hypertension, hyperlipidemia, fatty liver disease), weight reduction prior to pregnancy may decrease the risk of other pregnancy complications associated with obesity (eg, preeclampsia, some congenital anomalies, cesarean birth, macrosomia). (See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management"</a>.)</p><p>In adults with diabetes, regular exercise is important to improve glycemic control, assist with weight maintenance, and reduce the risk of cardiovascular disease and overall mortality. An appropriate exercise program for nonpregnant patients with diabetes is described separately (see  <a class="medical medical_review" href="/d/html/1777.html" rel="external">"Exercise guidance in adults with diabetes mellitus", section on 'Exercise guidance'</a>). Exercise can be maintained during pregnancy. (See  <a class="medical medical_review" href="/d/html/412.html" rel="external">"Exercise during pregnancy and the postpartum period"</a>.)</p><p class="headingAnchor" id="H9014834"><span class="h2">Folic acid and iodine supplementation</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> 400 micrograms/day is recommended for most reproductive-age females to decrease the occurrence of neural tube defects (NTDs).</p><p></p><p class="bulletIndent1">Because pregnant people with pregestational diabetes are at increased risk of having a child with an NTD, some authorities have opined that they may benefit from a higher dose of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> (0.8 to 5 mg per day) [<a href="#rid84">84,85,105</a>]; however, the optimum dose of folic acid in this population has not been studied, and recommendations vary. We agree with the ADA's recommendation for a minimum dose of at least 400 micrograms/day [<a href="#rid55">55</a>], which was effective in at least two case-control studies [<a href="#rid106">106,107</a>] and in at least one study in animals [<a href="#rid108">108</a>]. The recommended dietary allowance in pregnancy is 600 micrograms/day. (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation", section on 'Preexisting diabetes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females who are planning pregnancy or are currently pregnant should supplement their diet with a daily oral supplement that contains 150 micrograms of iodine in the form of potassium iodide [<a href="#rid55">55,109</a>].</p><p></p><p class="headingAnchor" id="H9014852"><span class="h2">Blood pressure control</span><span class="headingEndMark"> — </span>In pregnant patients with diabetes and chronic hypertension, the ADA suggests a blood pressure target of 110 to 135/85 mmHg [<a href="#rid55">55</a>], which aligns with data that all pregnant patients with chronic hypertension and blood pressures ≥140/90 mmHg should be treated [<a href="#rid110">110</a>]. However, there are minimal data to guide blood pressure targets in preconception and early pregnancy in patients with diabetes. Preferred agents for treatment of hypertension in pregnancy include <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, <a class="drug drug_general" data-topicid="9635" href="/d/drug information/9635.html" rel="external">methyldopa</a>, and extended-release <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a>. (See  <a class="medical medical_review" href="/d/html/116432.html" rel="external">"Chronic hypertension in pregnancy: Prenatal and postpartum care"</a>.)</p><p>Angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) should be discontinued and replaced with another class of antihypertensive drug (eg, <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a> or a long-acting calcium channel blocker) when patients with diabetes and hypertension are planning pregnancy and before stopping contraception (see  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a>). Although ACE inhibitors and ARBs are commonly used for management of hypertension and may be recommended for management of moderately increased albuminuria (formerly microalbuminuria) in nonpregnant individuals with diabetes, both classes of drugs are contraindicated in the second and third trimesters of pregnancy because they have been associated with fetal renal injury and neonatal renal failure [<a href="#rid111">111</a>]. Whether first-trimester exposure to these drugs is also teratogenic is controversial, but switching to an agent(s) with a better safety profile is prudent [<a href="#rid112">112,113</a>]. If not already discontinued, ACE inhibitors and ARBs should be stopped when pregnancy is confirmed. (See  <a class="medical medical_review" href="/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p class="headingAnchor" id="H9014858"><span class="h2">Lipid control</span><span class="headingEndMark"> — </span>Statins are usually discontinued in pregnancy because of limited and contradictory data as to whether there is an increased risk of congenital anomalies with first-trimester exposure [<a href="#rid114">114</a>]. This discordance may reflect confounding by indication. Accordingly, the US Food and Drug Administration (FDA) removed the words "contraindicated in pregnancy" in regard to statins in 2021 [<a href="#rid115">115</a>]. We suggest discontinuing statins in patients who are planning to become pregnant and resuming these drugs after birth/completion of breastfeeding. However, individual decisions need to be made about benefit versus risk in patients at very high risk of a myocardial infarction or stroke, such as those with homozygous familial hypercholesterolemia or established cardiovascular disease. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Risks in pregnancy and breastfeeding'</a>.)</p><p class="headingAnchor" id="H9014864"><span class="h2">Evaluation of and approach to complications of diabetes mellitus</span><span class="headingEndMark"> — </span>Evaluation for complications of diabetes should be up to date before patients attempt to conceive. We perform both physical examination  (<a class="graphic graphic_table graphicRef97118" href="/d/graphic/97118.html" rel="external">table 2</a>) and laboratory evaluation (A1C, serum creatinine, estimated glomerular filtration rate, aspartate aminotransferase and alanine aminotransferase, thyroid-stimulating hormone [TSH], urine albumin-to-creatinine ratio on a spot urine or 24-hour urine collection for protein and creatinine).</p><p>A baseline evaluation is important because some diabetes-related complications should be treated prior to conception (eg, retinopathy). In addition, this information is important for counseling and pregnancy management since some complications, such as diabetic kidney disease, are associated with an increased risk of pregnancy complications, may worsen during pregnancy, and may make the diagnosis of pregnancy complications (eg, preeclampsia) more difficult.</p><p class="headingAnchor" id="H9014870"><span class="h3">Diabetic kidney disease</span><span class="headingEndMark"> — </span>As discussed above (see <a class="local">'Diabetic kidney disease'</a> above), pregnancy does not appear to increase the risk of developing diabetic kidney disease if not present before pregnancy, but patients with established nephropathy can develop permanent worsening of renal functioning during pregnancy. The risk of permanent loss of renal function is significant in pregnant patients with uncontrolled hypertension, baseline serum creatinine &gt;1.5 mg/dL, or protein ≥3 grams in a 24-hour urine collection [<a href="#rid72">72,116</a>].</p><p>Patients with significant diabetic kidney disease should be referred to a nephrologist skilled in the care of pregnant people to assist them in balancing their desire for pregnancy and the risks and consequences of deterioration of renal function. (See  <a class="medical medical_review" href="/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p>Major treatment options for preservation of renal function in nonpregnant patients (ACE inhibitors or ARBs) are contraindicated in pregnancy. However, control of hypertension with agents preferred in pregnancy may be beneficial. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p class="headingAnchor" id="H9014876"><span class="h3">Retinopathy</span><span class="headingEndMark"> — </span>As discussed above (see <a class="local">'Diabetic retinopathy'</a> above), retinopathy can worsen during pregnancy, sometimes rapidly, and result in permanent loss of vision, although generally only in patients who started with advanced retinopathy in the pregravid state. To reduce this risk, patients with diabetes should have a dilated eye examination before pregnancy [<a href="#rid55">55,84</a>], and if proliferative retinopathy is detected, it should be treated prior to attempts at conception. Since exacerbation of retinopathy can occur with rapid control of glucose levels, improvement in glucose control should be made gradually over months prior to pregnancy, when possible. (See  <a class="medical medical_review" href="/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H9014882"><span class="h3">Gastroparesis</span><span class="headingEndMark"> — </span>Evaluation for gastroparesis (see <a class="local">'Peripheral and autonomic neuropathy'</a> above) is performed by history and physical examination after a meal. A report of nausea, vomiting, early satiety, postprandial fullness, abdominal pain, bloating, or presence of succussion splash suggests the diagnosis. In some cases, evaluation of gastric emptying by scintigraphy is performed to make a definitive diagnosis. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p>Initial management of gastroparesis consists of dietary modification, optimization of glycemic control, and hydration. In patients with continued symptoms, pharmacologic therapy with prokinetic and antiemetic medications with a good fetal safety profile may be needed (eg, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>). (See  <a class="medical medical_review" href="/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p class="headingAnchor" id="H9014888"><span class="h3">Cardiovascular disease</span><span class="headingEndMark"> — </span>Patients with type 1 or type 2 diabetes of long duration may have cardiovascular disease. Extended evaluation should be based on the patient's history and physical examination  (<a class="graphic graphic_table graphicRef97118" href="/d/graphic/97118.html" rel="external">table 2</a>). For example, a carotid bruit can be an indicator of ischemic cardiac disease, and angina may present as atypical chest pain or shortness of breath. Patients with abnormal cardiac findings on examination, electrocardiogram (ECG), or by history should be referred to a cardiologist for further evaluation (such as exercise tolerance testing), management, and counseling. (See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a>.)</p><p>The ADA recommends a preconception ECG for females ≥age 35 with diabetes who have cardiac signs/symptoms or risk factors; if the ECG is abnormal, further evaluation is indicated [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H9014894"><span class="h3">Thyroid disease</span><span class="headingEndMark"> — </span>Although not caused by diabetes, autoimmune thyroid dysfunction is frequently associated with type 1 diabetes; hypothyroidism is more common than hyperthyroidism. The American College of Obstetricians and Gynecologists, ADA, and Endocrine Society recommend screening patients with type 1 diabetes prior to pregnancy with a TSH level [<a href="#rid72">72,84,85</a>]. Hypothyroidism is treated with <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>. The TSH should be &lt;2.5 milliunits/mL before pregnancy is attempted [<a href="#rid117">117,118</a>]. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy"</a>.)</p><p>If the TSH is low, a thyroxine (T4) level should be obtained. Goals and medications for the treatment of hyperthyroidism prior to and during pregnancy are complex and should be managed by an endocrinologist or other clinician experienced in the management of hyperthyroidism during pregnancy. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment"</a>.)</p><p>Females with type 2 diabetes also have a higher prevalence of hypothyroidism than the general population. Whether this is a true association or confounding by indication due to increased testing is unclear; however, the ADA [<a href="#rid72">72</a>] recommends checking the TSH level prior to pregnancy in patients with type 2 diabetes and initiating treatment when indicated.</p><p>Routine measurement of antithyroid antibodies is not necessary for the assessment of thyroid function. Whether to treat euthyroid thyroid peroxidase antibody-positive females to improve pregnancy outcome is controversial and is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'Thyroid peroxidase antibodies in euthyroid women'</a>.)</p><p class="headingAnchor" id="H1058007970"><span class="h2">Contraception and timing of pregnancy</span><span class="headingEndMark"> — </span>Family planning with use of effective contraception until glucose control is achieved should be a key feature in the management of all females with diabetes and should be discussed at regular intervals. Given the importance of optimization of glucose control at conception, evaluation for and management of diabetes complications, and change in medication prior to conception, it is recommended that patients with prepregnancy diabetes plan their pregnancies to optimize the likelihood for a healthy pregnancy both for the mother and the baby.</p><p>Guidelines from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=94859" target="_blank">United States Centers for Disease Control and Prevention Medical Eligibility Criteria for Contraceptive Use</a> are helpful for advising patients with diabetes about the safety of contraceptive methods [<a href="#rid119">119</a>]. Estrogen-progestin and progestin-only contraceptives are safe and effective for many patients with type 1 or type 2 diabetes. However, patients with nephropathy, retinopathy, neuropathy, other vascular disease, or diabetes &gt;20 years in duration have conditions in which the theoretical or proven risks of using an estrogen-progestin method or depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> may outweigh the advantages of using the method or represent an unacceptable health risk if the contraceptive method is used. Other progestin-only methods (eg, pill, implant, intrauterine device [IUD]) and the copper-releasing IUD are preferable for patients with these conditions since they are associated with a lower rate of thromboembolic events than estrogen-progestin contraceptives [<a href="#rid120">120</a>]. Long-acting reversible contraception methods are generally most effective at preventing unplanned pregnancy. (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types"</a> and  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p>The selection of a contraceptive method for an individual patient should be based on the same guidelines that apply to patients without diabetes. Considerations of potential side effects of contraceptive agents should be weighed against the risk of an unplanned pregnancy.</p><p>Types of hormonal and nonhormonal contraception and important factors in choosing a contraceptive method are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p class="headingAnchor" id="H9014906"><span class="h2">Multidisciplinary programs</span><span class="headingEndMark"> — </span>Prior to and during pregnancy, patients with preexisting diabetes may benefit from being followed in a multidisciplinary care program with providers including an obstetrician, an endocrinologist (or other clinician with expertise in diabetes management in pregnancy), a dietician, and a diabetes educator (with other health professionals as needed). Data supporting the benefit of these programs in improving pregnancy outcomes are limited by the lack of randomized trials and the caveat that patients who are more motivated to manage their diabetes are likely to be those who attend these programs. Nevertheless, observational data, including a prospective cohort including both type 1 and type 2 diabetes, suggest that individuals who attend preconception programs have better pregnancy outcomes, including decreased congenital malformation, stillbirth, and neonatal mortality [<a href="#rid17">17,121</a>].</p><p class="headingAnchor" id="H247003528"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109438.html" rel="external">"Society guideline links: Diabetes mellitus in pregnancy"</a>.)</p><p class="headingAnchor" id="H1026761074"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16417.html" rel="external">"Patient education: Preparing for pregnancy when you have diabetes (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9014912"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Prior to pregnancy, all females of childbearing age with type 1 or type 2 diabetes should be counseled about the potential effects of diabetes on maternal and fetal outcomes and the potential impact of pregnancy on their diabetes control and any existing complications. The key components of preconception diabetes management are glycemic control, proficient diabetes self-care, and medical optimization of preexisting complications and comorbidities associated with diabetes. Patient education also includes insulin management, prevention and identification of hypoglycemia and diabetic ketoacidosis, and diet and exercise counseling. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy risks</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of adverse pregnancy outcome is increased in pregnant people with diabetes but appears to be similar for type 1 versus type 2 diabetes. Pregnant people with type 1 diabetes are more likely to have microvascular-disease-related complications than those with type 2 diabetes, and they are at higher risk of developing severe hypo- and hyperglycemia. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adverse pregnancy outcomes include miscarriage, congenital anomaly, macrosomia, preeclampsia, preterm birth, cesarean birth, and perinatal mortality. Short- and long-term morbidity in offspring are also concerns. Maternal medical risks include progression of retinopathy and nephropathy, diabetic ketoacidosis, serious hypoglycemia, and complications related to gastroparesis. (See <a class="local">'Risk counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preconception glucose/A1C targets</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperglycemia in the periconception period and during the course of pregnancy is the single most important determinant of excess risk of adverse fetal outcome in pregnant people with pregestational diabetes. Achieving preconception glycemic control as close to normal as possible while avoiding hypoglycemia is of critical importance. (See <a class="local">'General principles'</a> above and <a class="local">'Risk counseling'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Our primary preconception A1C goal for all patients is A1C &lt;6.5 percent. Glucose targets are fasting capillary blood glucose concentration 80 to 110 mg/dL (4.4 to 6.1 mmol/L) and two-hour postprandial glucose concentration &lt;155 mg/dL (8.6 mmol/L). Although still quite low, these targets are slightly higher than pregnancy targets and probably more pragmatic for patients who are not yet pregnant. (See <a class="local">'Glycemic control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preconception management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraception</strong> – Contraception is recommended until glycemic control is achieved, management of complications or comorbidities is optimized, and pregnancy is desired. (See <a class="local">'Contraception and timing of pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory evaluation</strong> – Preconception evaluation includes physical examination  (<a class="graphic graphic_table graphicRef97118" href="/d/graphic/97118.html" rel="external">table 2</a>) and laboratory evaluation (glycated hemoglobin [A1C], serum creatinine, estimated glomerular filtration rate, aspartate aminotransferase and alanine aminotransferase, thyroid-stimulating hormone, urine albumin-to-creatinine ratio on a spot urine or 24-hour urine collection for protein and creatinine). Further evaluation may be indicated based on the patient's history and examination. (See <a class="local">'Evaluation of and approach to complications of diabetes mellitus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a><strong> supplementation</strong> – We agree with the American Diabetes Association's (ADA) recommendation for supplemental folic acid 400 micrograms/day and potassium iodide 150 micrograms/day. (See <a class="local">'Folic acid and iodine supplementation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacotherapy</strong> – Insulin is the preferred treatment for hyperglycemia in pregnancy. In patients with type 2 diabetes on <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> monotherapy with adequate glycemic control for preconception, we initiate insulin once pregnancy is confirmed. Other non-insulin agents should be stopped and substituted with insulin prior to conception. (See <a class="local">'Glycemic control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avoid angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and statins</strong> – These drugs should be discontinued before pregnancy is attempted. (See <a class="local">'Blood pressure control'</a> above and <a class="local">'Lipid control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastroparesis</strong> – Gastroparesis may influence dietary approach, insulin regimen, and other medical therapies. Severe gastroparesis is one of the few relative contraindications to pregnancy. (See <a class="local">'Gastroparesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diabetic kidney disease</strong> – Patients with significant diabetic kidney disease should be referred to a nephrologist skilled in the care of pregnant patients to assist them in balancing their desire for pregnancy and the risks and consequences of deterioration of renal function. Patients with established nephropathy may develop permanent worsening of renal functioning during pregnancy. (See <a class="local">'Diabetic kidney disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ophthalmology evaluation</strong> – A dilated eye examination should be performed before pregnancy, and if proliferative retinopathy is detected, it should be treated prior to attempts at conception. Diabetic retinopathy can worsen during pregnancy. (See <a class="local">'Retinopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac evaluation</strong> – Signs and symptoms of cardiovascular disease on history or physical examination (eg, carotid bruits, absent peripheral pulse) are an indication for further cardiac evaluation and possible referral to a cardiologist. (See <a class="local">'Cardiovascular disease'</a> above.)</p><p></p><p class="headingAnchor" id="H2254080634"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael F Greene, MD, and Emma B Morton-Eggleston, MD, MPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Albrecht SS, Kuklina EV, Bansil P, et al. Diabetes trends among delivery hospitalizations in the U.S., 1994-2004. Diabetes Care 2010; 33:768.</a></li><li><a class="nounderline abstract_t">Deputy NP, Kim SY, Conrey EJ, Bullard KM. Prevalence and Changes in Preexisting Diabetes and Gestational Diabetes Among Women Who Had a Live Birth - United States, 2012-2016. MMWR Morb Mortal Wkly Rep 2018; 67:1201.</a></li><li><a class="nounderline abstract_t">Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047.</a></li><li><a class="nounderline abstract_t">Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.</a></li><li><a class="nounderline abstract_t">Peng TY, Ehrlich SF, Crites Y, et al. Trends and racial and ethnic disparities in the prevalence of pregestational type 1 and type 2 diabetes in Northern California: 1996-2014. Am J Obstet Gynecol 2017; 216:177.e1.</a></li><li><a class="nounderline abstract_t">Feig DS. Epidemiology and Therapeutic Strategies for Women With Preexisting Diabetes in Pregnancy: How Far Have We Come? The 2021 Norbert Freinkel Award Lecture. Diabetes Care 2022; 45:2484.</a></li><li><a class="nounderline abstract_t">Kitzmiller JL, Wallerstein R, Correa A, Kwan S. Preconception care for women with diabetes and prevention of major congenital malformations. Birth Defects Res A Clin Mol Teratol 2010; 88:791.</a></li><li><a class="nounderline abstract_t">Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 2004; 328:915.</a></li><li><a class="nounderline abstract_t">Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, population-based study. Diabetes Care 2009; 32:2005.</a></li><li><a class="nounderline abstract_t">Tennant PW, Glinianaia SV, Bilous RW, et al. Pre-existing diabetes, maternal glycated haemoglobin, and the risks of fetal and infant death: a population-based study. Diabetologia 2014; 57:285.</a></li><li><a class="nounderline abstract_t">Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 2009; 32:1046.</a></li><li><a class="nounderline abstract_t">Wahabi HA, Fayed A, Esmaeil S, et al. Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes. PLoS One 2020; 15:e0237571.</a></li><li><a class="nounderline abstract_t">Singh H, Murphy HR, Hendrieckx C, et al. The challenges and future considerations regarding pregnancy-related outcomes in women with pre-existing diabetes. Curr Diab Rep 2013; 13:869.</a></li><li><a class="nounderline abstract_t">Do NC, Secher AL, Cramon P, et al. Quality of life, anxiety and depression symptoms in early and late pregnancy in women with pregestational diabetes. Acta Obstet Gynecol Scand 2017; 96:190.</a></li><li><a class="nounderline abstract_t">Ehrenberg HM, Mercer BM, Catalano PM. The influence of obesity and diabetes on the prevalence of macrosomia. Am J Obstet Gynecol 2004; 191:964.</a></li><li><a class="nounderline abstract_t">Cundy T, Gamble G, Neale L, et al. Differing causes of pregnancy loss in type 1 and type 2 diabetes. Diabetes Care 2007; 30:2603.</a></li><li><a class="nounderline abstract_t">Murphy HR, Roland JM, Skinner TC, et al. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control. Diabetes Care 2010; 33:2514.</a></li><li><a class="nounderline abstract_t">Al-Agha R, Firth RG, Byrne M, et al. Outcome of pregnancy in type 1 diabetes mellitus (T1DMP): results from combined diabetes-obstetrical clinics in Dublin in three university teaching hospitals (1995-2006). Ir J Med Sci 2012; 181:105.</a></li><li><a class="nounderline abstract_t">Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007; 30:1920.</a></li><li><a class="nounderline abstract_t">Bell R, Glinianaia SV, Tennant PW, et al. Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. Diabetologia 2012.</a></li><li><a class="nounderline abstract_t">Tinker SC, Gilboa SM, Moore CA, et al. Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011. Am J Obstet Gynecol 2020; 222:176.e1.</a></li><li><a class="nounderline abstract_t">Schaefer-Graf UM, Buchanan TA, Xiang A, et al. Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes. Am J Obstet Gynecol 2000; 182:313.</a></li><li><a class="nounderline abstract_t">Al Kaissi A, Klaushofer K, Grill F. Caudal regression syndrome and popliteal webbing in connection with maternal diabetes mellitus: a case report and literature review. Cases J 2008; 1:407.</a></li><li><a class="nounderline abstract_t">Salbaum JM, Kappen C. Responses of the embryonic epigenome to maternal diabetes. Birth Defects Res A Clin Mol Teratol 2012; 94:770.</a></li><li><a class="nounderline abstract_t">Pavlinkova G, Salbaum JM, Kappen C. Maternal diabetes alters transcriptional programs in the developing embryo. BMC Genomics 2009; 10:274.</a></li><li><a class="nounderline abstract_t">Sato N, Sugimura Y, Hayashi Y, et al. Identification of genes differentially expressed in mouse fetuses from streptozotocin-induced diabetic pregnancy by cDNA subtraction. Endocr J 2008; 55:317.</a></li><li><a class="nounderline abstract_t">Gabbay-Benziv R, Reece EA, Wang F, Yang P. Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis. World J Diabetes 2015; 6:481.</a></li><li><a class="nounderline abstract_t">Tinker SC, Gilboa SM, Moore CA, et al. Modification of the association between diabetes and birth defects by obesity, National Birth Defects Prevention Study, 1997-2011. Birth Defects Res 2021; 113:1084.</a></li><li><a class="nounderline abstract_t">Sibai BM, Caritis SN, Hauth JC, et al. Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. The National institute of Child health and Human Development Maternal- Fetal Medicine Units Network. Am J Obstet Gynecol 2000; 183:1520.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Neovius M, Söderling J, et al. Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study. Ann Intern Med 2019; 170:691.</a></li><li><a class="nounderline abstract_t">Haeri S, Khoury J, Kovilam O, Miodovnik M. The association of intrauterine growth abnormalities in women with type 1 diabetes mellitus complicated by vasculopathy. Am J Obstet Gynecol 2008; 199:278.e1.</a></li><li><a class="nounderline abstract_t">McFarland MB, Trylovich CG, Langer O. Anthropometric differences in macrosomic infants of diabetic and nondiabetic mothers. J Matern Fetal Med 1998; 7:292.</a></li><li><a class="nounderline abstract_t">Gold AE, Reilly R, Little J, Walker JD. The effect of glycemic control in the pre-conception period and early pregnancy on birth weight in women with IDDM. Diabetes Care 1998; 21:535.</a></li><li><a class="nounderline abstract_t">Schaefer-Graf U, Napoli A, Nolan CJ, Diabetic Pregnancy Study Group. Diabetes in pregnancy: a new decade of challenges ahead. Diabetologia 2018; 61:1012.</a></li><li><a class="nounderline abstract_t">Balsells M, García-Patterson A, Gich I, Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab 2009; 94:4284.</a></li><li><a class="nounderline abstract_t">Cundy T, Gamble G, Townend K, et al. Perinatal mortality in Type 2 diabetes mellitus. Diabet Med 2000; 17:33.</a></li><li><a class="nounderline abstract_t">Murphy HR, Bell R, Cartwright C, et al. Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. Diabetologia 2017; 60:1668.</a></li><li><a class="nounderline abstract_t">Murphy HR. Intensive Glycemic Treatment During Type 1 Diabetes Pregnancy: A Story of (Mostly) Sweet Success! Diabetes Care 2018; 41:1563.</a></li><li><a class="nounderline abstract_t">McElvy SS, Miodovnik M, Rosenn B, et al. A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med 2000; 9:14.</a></li><li><a class="nounderline abstract_t">Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care 2008; 31:340.</a></li><li><a class="nounderline abstract_t">Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes Care 1995; 18:611.</a></li><li><a class="nounderline abstract_t">Pettitt DJ, Nelson RG, Saad MF, et al. Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care 1993; 16:310.</a></li><li><a class="nounderline abstract_t">Dabelea D, Mayer-Davis EJ, Lamichhane AP, et al. Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study. Diabetes Care 2008; 31:1422.</a></li><li><a class="nounderline abstract_t">Nolan CJ. Normal long-term health for infants of diabetic mothers: can we achieve it? J Clin Endocrinol Metab 2013; 98:3592.</a></li><li><a class="nounderline abstract_t">Wu CS, Nohr EA, Bech BH, et al. Long-term health outcomes in children born to mothers with diabetes: a population-based cohort study. PLoS One 2012; 7:e36727.</a></li><li><a class="nounderline abstract_t">Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J Pediatr Endocrinol Metab 2001; 14:1085.</a></li><li><a class="nounderline abstract_t">Xiang AH, Wang X, Martinez MP, et al. Association of maternal diabetes with autism in offspring. JAMA 2015; 313:1425.</a></li><li><a class="nounderline abstract_t">Xiang AH, Wang X, Martinez MP, et al. Maternal Type 1 Diabetes and Risk of Autism in Offspring. JAMA 2018; 320:89.</a></li><li><a class="nounderline abstract_t">Hewapathirana NM, Murphy HR. Perinatal outcomes in type 2 diabetes. Curr Diab Rep 2014; 14:461.</a></li><li><a class="nounderline abstract_t">Ballas J, Moore TR, Ramos GA. Management of diabetes in pregnancy. Curr Diab Rep 2012; 12:33.</a></li><li><a class="nounderline abstract_t">Sibai BM, Caritis S, Hauth J, et al. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 2000; 182:364.</a></li><li><a class="nounderline abstract_t">Vestgaard M, Sommer MC, Ringholm L, et al. Prediction of preeclampsia in type 1 diabetes in early pregnancy by clinical predictors: a systematic review. J Matern Fetal Neonatal Med 2018; 31:1933.</a></li><li><a class="nounderline abstract_t">Howarth C, Gazis A, James D. Associations of Type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy. Diabet Med 2007; 24:1229.</a></li><li><a class="nounderline abstract_t">Temple RC, Aldridge V, Stanley K, Murphy HR. Glycaemic control throughout pregnancy and risk of pre-eclampsia in women with type I diabetes. BJOG 2006; 113:1329.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S232.</a></li><li><a class="nounderline abstract_t">Idris N, Wong SF, Thomae M, et al. Influence of polyhydramnios on perinatal outcome in pregestational diabetic pregnancies. Ultrasound Obstet Gynecol 2010; 36:338.</a></li><li><a class="nounderline abstract_t">Vink JY, Poggi SH, Ghidini A, Spong CY. Amniotic fluid index and birth weight: is there a relationship in diabetics with poor glycemic control? Am J Obstet Gynecol 2006; 195:848.</a></li><li><a class="nounderline abstract_t">Evers IM, ter Braak EW, de Valk HW, et al. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care 2002; 25:554.</a></li><li><a class="nounderline abstract_t">Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycaemia during pregnancy in women with Type 1 diabetes. Diabet Med 2012; 29:558.</a></li><li><a class="nounderline abstract_t">García-Patterson A, Gich I, Amini SB, et al. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. Diabetologia 2010; 53:446.</a></li><li><a class="nounderline abstract_t">Powe CE, Huston Presley LP, Locascio JJ, Catalano PM. Augmented insulin secretory response in early pregnancy. Diabetologia 2019; 62:1445.</a></li><li><a class="nounderline abstract_t">Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care 2008; 31:9.</a></li><li><a class="nounderline abstract_t">Arun CS, Taylor R. Influence of pregnancy on long-term progression of retinopathy in patients with type 1 diabetes. Diabetologia 2008; 51:1041.</a></li><li><a class="nounderline abstract_t">Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23:1084.</a></li><li><a class="nounderline abstract_t">Vérier-Mine O, Chaturvedi N, Webb D, Fuller JH. Is pregnancy a risk factor for microvascular complications? The EURODIAB Prospective Complications Study. Diabet Med 2005; 22:1503.</a></li><li><a class="nounderline abstract_t">Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia 2010; 53:1076.</a></li><li><a class="nounderline abstract_t">Chan WC, Lim LT, Quinn MJ, et al. Management and outcome of sight-threatening diabetic retinopathy in pregnancy. Eye (Lond) 2004; 18:826.</a></li><li><a class="nounderline abstract_t">Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631.</a></li><li><a class="nounderline abstract_t">Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13:34.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2004; 27 Suppl 1:S76.</a></li><li><a class="nounderline abstract_t">Relph S, Patel T, Delaney L, et al. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis. PLoS Med 2021; 18:e1003856.</a></li><li><a class="nounderline abstract_t">Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008; 31:1060.</a></li><li><a class="nounderline abstract_t">Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26:2433.</a></li><li><a class="nounderline abstract_t">Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005; 90:5896.</a></li><li><a class="nounderline abstract_t">Parker JA, Conway DL. Diabetic ketoacidosis in pregnancy. Obstet Gynecol Clin North Am 2007; 34:533.</a></li><li><a class="nounderline abstract_t">Sibai BM, Viteri OA. Diabetic ketoacidosis in pregnancy. Obstet Gynecol 2014; 123:167.</a></li><li><a class="nounderline abstract_t">Cullen MT, Reece EA, Homko CJ, Sivan E. The changing presentations of diabetic ketoacidosis during pregnancy. Am J Perinatol 1996; 13:449.</a></li><li><a class="nounderline abstract_t">Montoro MN, Myers VP, Mestman JH, et al. Outcome of pregnancy in diabetic ketoacidosis. Am J Perinatol 1993; 10:17.</a></li><li><a class="nounderline abstract_t">Schneider MB, Umpierrez GE, Ramsey RD, et al. Pregnancy complicated by diabetic ketoacidosis: maternal and fetal outcomes. Diabetes Care 2003; 26:958.</a></li><li><a class="nounderline abstract_t">Carreira E, Lepercq J, Bouché C, et al. Uneventful pregnancy in a patient with ketosis-prone type 2 diabetes mellitus. Diabetes Metab 2008; 34:182.</a></li><li><a class="nounderline abstract_t">Wahabi HA, Alzeidan RA, Bawazeer GA, et al. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2010; 10:63.</a></li><li><a class="nounderline abstract_t">Gregory R, Tattersall RB. Are diabetic pre-pregnancy clinics worth while? Lancet 1992; 340:656.</a></li><li><a class="nounderline abstract_t">Schaefer UM, Songster G, Xiang A, et al. Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy. Am J Obstet Gynecol 1997; 177:1165.</a></li><li><a class="nounderline abstract_t">Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013; 98:4227.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol 2018; 132:e228. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49:999.</a></li><li><a class="nounderline abstract_t">Gallen IW, Jaap A, Roland JM, Chirayath HH. Survey of glargine use in 115 pregnant women with Type 1 diabetes. Diabet Med 2008; 25:165.</a></li><li><a class="nounderline abstract_t">Pöyhönen-Alho M, Rönnemaa T, Saltevo J, et al. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand 2007; 86:1171.</a></li><li><a class="nounderline abstract_t">Di Cianni G, Torlone E, Lencioni C, et al. Perinatal outcomes associated with the use of glargine during pregnancy. Diabet Med 2008; 25:993.</a></li><li><a class="nounderline abstract_t">Keller MF, Vestgaard M, Damm P, et al. Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases. Diabetes Res Clin Pract 2019; 152:58.</a></li><li class="breakAll">Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes (EXPECT) https://clinicaltrials.gov/ct2/show/NCT03377699 (Accessed on May 13, 2021).</li><li><a class="nounderline abstract_t">Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30:771.</a></li><li><a class="nounderline abstract_t">O'Neill SM, Kenny LC, Khashan AS, et al. Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev 2017; 2:CD011880.</a></li><li><a class="nounderline abstract_t">Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017; 390:2347.</a></li><li><a class="nounderline abstract_t">Feig DS, Corcoy R, Donovan LE, et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care 2018; 41:2471.</a></li><li><a class="nounderline abstract_t">Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA 2016; 316:1407.</a></li><li><a class="nounderline abstract_t">Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86:658.</a></li><li><a class="nounderline abstract_t">Cassina M, Donà M, Di Gianantonio E, et al. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:656.</a></li><li><a class="nounderline abstract_t">Dukhovny S, Van Bennekom CM, Gagnon DR, et al. Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. Birth Defects Res 2018; 110:579.</a></li><li><a class="nounderline abstract_t">Given JE, Loane M, Garne E, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ 2018; 361:k2477.</a></li><li><a class="nounderline abstract_t">Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2020; 8:834.</a></li><li><a class="nounderline abstract_t">Schwartz RA, Rosenn B, Aleksa K, Koren G. Glyburide transport across the human placenta. Obstet Gynecol 2015; 125:583.</a></li><li><a class="nounderline abstract_t">Camelo Castillo W, Boggess K, Stürmer T, et al. Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. JAMA Pediatr 2015; 169:452.</a></li><li><a class="nounderline abstract_t">Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med 2023.</a></li><li><a class="nounderline abstract_t">Wilson RD, Genetics Committee, Wilson RD, et al. Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies. J Obstet Gynaecol Can 2015; 37:534.</a></li><li><a class="nounderline abstract_t">Correa A, Gilboa SM, Botto LD, et al. Lack of periconceptional vitamins or supplements that contain folic acid and diabetes mellitus-associated birth defects. Am J Obstet Gynecol 2012; 206:218.e1.</a></li><li><a class="nounderline abstract_t">Parker SE, Yazdy MM, Tinker SC, et al. The impact of folic acid intake on the association among diabetes mellitus, obesity, and spina bifida. Am J Obstet Gynecol 2013; 209:239.e1.</a></li><li><a class="nounderline abstract_t">Wentzel P, Gäreskog M, Eriksson UJ. Folic acid supplementation diminishes diabetes- and glucose-induced dysmorphogenesis in rat embryos in vivo and in vitro. Diabetes 2005; 54:546.</a></li><li><a class="nounderline abstract_t">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017; 27:315.</a></li><li class="breakAll">Clinical Guidance for the Integration of the Findingsof the Chronic Hypertension and Pregnancy (CHAP) Study. Practice Advisory. 2022. Available at: https://www.acog.org/ (Accessed on April 14, 2022).</li><li><a class="nounderline abstract_t">Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60:444.</a></li><li><a class="nounderline abstract_t">Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.</a></li><li><a class="nounderline abstract_t">Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343:d5931.</a></li><li><a class="nounderline abstract_t">Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ 2015; 350:h1035.</a></li><li class="breakAll">US Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. July 2021. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy (Accessed on July 20, 2021).</li><li><a class="nounderline abstract_t">Hoffmann K, Heller R. Uniparental disomies 7 and 14. Best Pract Res Clin Endocrinol Metab 2011; 25:77.</a></li><li><a class="nounderline abstract_t">De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2543.</a></li><li><a class="nounderline abstract_t">Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">O'Brien SH, Koch T, Vesely SK, Schwarz EB. Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes. Diabetes Care 2017; 40:233.</a></li><li><a class="nounderline abstract_t">Josse J, James J, Roland J. Diabetes control in pregnancy: who takes responsibility for what? Pract Diabetes Int 2003; 20:290.</a></li></ol></div><div id="topicVersionRevision">Topic 94859 Version 64.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067968" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diabetes trends among delivery hospitalizations in the U.S., 1994-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383743" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence and Changes in Preexisting Diabetes and Gestational Diabetes Among Women Who Had a Live Birth - United States, 2012-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111519" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595272" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence of diabetes in youth in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27751798" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Trends and racial and ethnic disparities in the prevalence of pregestational type 1 and type 2 diabetes in Northern California: 1996-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37579297" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology and Therapeutic Strategies for Women With Preexisting Diabetes in Pregnancy: How Far Have We Come? The 2021 Norbert Freinkel Award Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890938" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Preconception care for women with diabetes and prevention of major congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15066886" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675195" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24292565" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pre-existing diabetes, maternal glycated haemoglobin, and the risks of fetal and infant death: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265024" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32810195" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013963" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The challenges and future considerations regarding pregnancy-related outcomes in women with pre-existing diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27779764" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Quality of life, anxiety and depression symptoms in early and late pregnancy in women with pregestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15467573" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The influence of obesity and diabetes on the prevalence of macrosomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17586739" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Differing causes of pregnancy loss in type 1 and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115765" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22057636" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outcome of pregnancy in type 1 diabetes mellitus (T1DMP): results from combined diabetes-obstetrical clinics in Dublin in three university teaching hospitals (1995-2006).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446531" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22314812" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31454511" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694330" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19099562" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Caudal regression syndrome and popliteal webbing in connection with maternal diabetes mellitus: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22786762" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Responses of the embryonic epigenome to maternal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19538749" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Maternal diabetes alters transcriptional programs in the developing embryo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18323671" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of genes differentially expressed in mouse fetuses from streptozotocin-induced diabetic pregnancy by cDNA subtraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25897357" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33876578" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Modification of the association between diabetes and birth defects by obesity, National Birth Defects Prevention Study, 1997-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120521" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. The National institute of Child health and Human Development Maternal- Fetal Medicine Units Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31009941" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771982" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The association of intrauterine growth abnormalities in women with type 1 diabetes mellitus complicated by vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848695" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anthropometric differences in macrosomic infants of diabetic and nondiabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9571338" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effect of glycemic control in the pre-conception period and early pregnancy on birth weight in women with IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29356835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diabetes in pregnancy: a new decade of challenges ahead.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808847" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691157" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Perinatal mortality in Type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28597075" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29936423" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intensive Glycemic Treatment During Type 1 Diabetes Pregnancy: A Story of (Mostly) Sweet Success!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757430" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000174" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8585997" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8422798" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375420" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24014814" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Normal long-term health for infants of diabetic mothers: can we achieve it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22649497" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long-term health outcomes in children born to mothers with diabetes: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11592564" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25871668" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association of maternal diabetes with autism in offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29936530" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Maternal Type 1 Diabetes and Risk of Autism in Offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24395435" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Perinatal outcomes in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22139557" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Management of diabetes in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694338" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28574296" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prediction of preeclampsia in type 1 diabetes in early pregnancy by clinical predictors: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17725628" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Associations of Type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17004981" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Glycaemic control throughout pregnancy and risk of pre-eclampsia in women with type I diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34964864" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20503236" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Influence of polyhydramnios on perinatal outcome in pregestational diabetic pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949424" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Amniotic fluid index and birth weight: is there a relationship in diabetics with poor glycemic control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874946" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22313112" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hypoglycaemia during pregnancy in women with Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20013109" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177313" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Augmented insulin secretory response in early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909091" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18392803" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Influence of pregnancy on long-term progression of retinopathy in patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10937502" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16241914" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Is pregnancy a risk factor for microvascular complications? The EURODIAB Prospective Complications Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20225131" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976547" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Management and outcome of sight-threatening diabetic retinopathy in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8586000" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404715" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of pregnancy on progression of diabetic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693933" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Preconception care of women with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34807920" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445730" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12882875" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Heart failure: the frequent, forgotten, and often fatal complication of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014401" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17921013" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Diabetic ketoacidosis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463678" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Diabetic ketoacidosis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960616" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The changing presentations of diabetic ketoacidosis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442791" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Outcome of pregnancy in diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610076" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pregnancy complicated by diabetic ketoacidosis: maternal and fetal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18329311" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Uneventful pregnancy in a patient with ketosis-prone type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946676" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1355220" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Are diabetic pre-pregnancy clinics worth while?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396914" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24194617" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diabetes and pregnancy: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30461693" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10866053" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18215174" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Survey of glargine use in 115 pregnant women with Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17851816" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Use of insulin glargine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18959615" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Perinatal outcomes associated with the use of glargine during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31102682" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31102682" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392539" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28156005" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Different insulin types and regimens for pregnant women with pre-existing diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28923465" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30327362" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27629148" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16879826" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24861556" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29388358" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941493" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32946820" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25730219" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Glyburide transport across the human placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25822253" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38079178" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26334606" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284962" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Lack of periconceptional vitamins or supplements that contain folic acid and diabetes mellitus-associated birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23711668" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The impact of folic acid intake on the association among diabetes mellitus, obesity, and spina bifida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677514" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Folic acid supplementation diminishes diabetes- and glucose-induced dysmorphogenesis in rat embryos in vivo and in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056690" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056690" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753220" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760444" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Major congenital malformations after first-trimester exposure to ACE inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010128" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784688" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Statins and congenital malformations: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25784688" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Statins and congenital malformations: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396576" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Uniparental disomies 7 and 14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869843" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787128" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27899496" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Diabetes control in pregnancy: who takes responsibility for what?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
